<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">469049626</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180323132826.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170328e19920301xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/BF02973989</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/BF02973989</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">Sex-related differences in rat hepatic cytochromes P450 expression following treatment with phenobarbital or 3-methylcholanthrene</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[Yoon Lee, Sang Park, Nak Kim]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">The induction of hepatic cytochromes P450 and metabolic effects have been examined in male and female Sprague-Dawley rats following treatment with either phenobarbital or 3-methylcholanthrene. Hepatic cytochrome P450 levels were higher in males than in females by ≈40%. Treatment of male and female rats with phenobarbital or 3-methylcholanthrene resulted in an ≈1.6- and 2-fold increase, respectively, in heptic microsomal cytochrome P450 levels in both sexes, relative to untreated animals. Immunoblot analyses were performed to compare sex-related changes in P450 levels. Hepatic P450IIB1 levels in males were greater than those in females following phenobarbital treatment. 3-Methylcholanthrene-induced male hepatic microsomes exhibited greater levels of P450 IA1 and IA2 than female microsomes, whereas uninduced microsomes from males or females failed to exhibit a band. Mab PCN 2-13-1 against P450IIIA recognized an intense band in uninduced hepatic microsomes from males whereas no band was recognized in uninduced microsomes from female rats. The levels of P450IIIA in males were increased 2 to 3-fold following treatment with phenobarbital. while the increase of IIIA levels in females by phenobarbital was minimal, as monitored by immunoblot analysis. Solid phase radioimmunoassay using monoclonal antibodies supported the results of immunoblot analysis. Phenobarbital treatment caused a 6.5-fold increase in the monoclonal antibody binding to IIB1 in males, whereas treatment of females with phenobarbital resulted in a 12-fold increase of IIB1 binding, relative to respective controls. The relative increase of IA levels by 3-methylcholanthrene was also greater in females than in males (10-vs. 8-fold) although the levels of induced IA were comparable in both sexes, as assessed by radioimmunoassay. Radioimmunoassay also showed that hepatic IIE1 level was 1.5-fold higher in males than in females and that either phenobarbital or 3-methylcholanthrene treatment caused 80% to 40% decrease in IIE1 levels, relative to control, in both sexes. Sex-related metabolic activities were examined in hepatic microsomes. Hexobarbital hydroxylase activity was 2- to 3-fold higher in uninduced microsomes from males than that from females. This hydroxylase activity was increased 2- and 3-fold in males and females, respectively, following phenobarbital treatment, as compared to controls. Addition of anti-P450IIB1 antibody to phenobarbital-induced hepatic microsomes from males and females produced 64% and 84% inhibition of hexobarbital oxidation, respectively. Aryl hydrocarbon hydroxylase activity was increased ≈12- and 26-fold in males and females. respectively, following 3-methylcholanthrene treatment relative to controls. The anti-P450IA antibody inhibitable rate of aryl hydrocarbon hydroxylase activity was comparable in both sexes following 3-methylcholanthrene treatment (≈70%). These results demonstrate that levels of hepatic P450IIB1 or P450IA are greater in male than in female for untreated, phenobarbital- or 3-methylcholanthrene treated rats. In addition, the relative increase of P450IIB1 or IA by phenobarbital or 3-methylcholanthrene is more significant in females.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">The Pharmaceutical Society of Korea, 1992</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Hepatic cytochrome P450</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">sex differences</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">phenobarbital</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">3-methylcholanthrene</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">monoclonal antibodies</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">hexobarbital hydroxylase</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">aryl hydrocarbon hydroxylase</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">HPLC : High pressure liquid chromatography</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">PB : phenobarbital</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">3-MC : 3-methylcholanthrene</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">PCN : pregnenolone 16α-carbonitrile</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">P450 : cytochrome P450</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Mab : monoclonal antibody</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">IA, IIB and IIE : cytochromes P450IA, IIB and IIE (genes CYPIA, CYP2B and CYP2E) are the nomenclature recommended for members of these subfamilies which include P450IA1 and IA2, IIB1 and IIB2, and IIE1 in rats (Nebertet al., 1991, DNA and cell biology) 10, 1-14</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Lee</subfield>
   <subfield code="D">Yoon</subfield>
   <subfield code="u">College of Pharmacy, Seoul National University, Seoul, Korea</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Park</subfield>
   <subfield code="D">Sang</subfield>
   <subfield code="u">Laboratory of Comparative Carcinogenesis, NCl-Frederick Cancer Research and Development Center, Frederick, MD, U.S.A.</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Kim</subfield>
   <subfield code="D">Nak</subfield>
   <subfield code="u">College of Pharmacy, Seoul National University, Seoul, Korea</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Archives of Pharmacal Research</subfield>
   <subfield code="d">Pharmaceutical Society of Korea</subfield>
   <subfield code="g">15/1(1992-03-01), 78-86</subfield>
   <subfield code="x">0253-6269</subfield>
   <subfield code="q">15:1&lt;78</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">15</subfield>
   <subfield code="o">12272</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/BF02973989</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/BF02973989</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Lee</subfield>
   <subfield code="D">Yoon</subfield>
   <subfield code="u">College of Pharmacy, Seoul National University, Seoul, Korea</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Park</subfield>
   <subfield code="D">Sang</subfield>
   <subfield code="u">Laboratory of Comparative Carcinogenesis, NCl-Frederick Cancer Research and Development Center, Frederick, MD, U.S.A</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Kim</subfield>
   <subfield code="D">Nak</subfield>
   <subfield code="u">College of Pharmacy, Seoul National University, Seoul, Korea</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Archives of Pharmacal Research</subfield>
   <subfield code="d">Pharmaceutical Society of Korea</subfield>
   <subfield code="g">15/1(1992-03-01), 78-86</subfield>
   <subfield code="x">0253-6269</subfield>
   <subfield code="q">15:1&lt;78</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">15</subfield>
   <subfield code="o">12272</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
